Patents by Inventor Roger Ronn

Roger Ronn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS
    Publication number: 20200048609
    Abstract: Maturation signals provided via cyclic adenosine monophosphate (cAMP)/Exchange proteins activated by cAMP (Epac) signaling during in vitro generation of blood cells from reprogrammed cells or pluripotent stem cells achieve superior function of hematopoietic cells differentiated from stem cells. The cAMP/Epac signaling enables an increased efficiency of production of precursor to blood and to blood cells. These generated blood cells can be utilized for therapeutics, treatments, disease prevention, drug discovery, personalized medicine, regenerative medicine, cell and tissue generation, universal donor banks and related methods and compositions.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 13, 2020
    Inventors: Shobhit SAXENA, Roger RÖNN
  • COMPOSITIONS AND METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO PRIMITIVE BLOOD CELLS AND USES THEREOF
    Publication number: 20160369235
    Abstract: Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGF?1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.
    Type: Application
    Filed: August 29, 2016
    Publication date: December 22, 2016
    Applicant: Primorigen Biosciences, Inc.
    Inventors: Niels-Bjarne Woods, Roger Ronn, Carolina Guibentif
  • Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
    Patent number: 9428732
    Abstract: Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGF?1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: August 30, 2016
    Assignee: Primorigen Biosciences, Inc.
    Inventors: Niels-Bjarne Woods, Roger Ronn, Carolina Guibentif